Fluicell

Fluicell Equity Ratio

The Equity Ratio of Fluicell (FLUI.ST) as of Nov 20, 2026 is 59.00 %. In the previous year, Equity Ratio was 75.40 % — a change of -21.75% (lower).

Equity Ratio

59.00 %

YoY

-21.75%

Last updated:

Equity Ratio of Fluicell is 2025 59.00 % . Equity Ratio of Fluicell was 2024 75.40 % . It decreases by -21.75% lower compared to the previous year.

The Fluicell Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
89.99 SEK
Jan 1, 2019
51.29 SEK
Jan 1, 2020
78.53 SEK
Jan 1, 2021
70.83 SEK
Jan 1, 2022
73.81 SEK
Jan 1, 2023
4.55 SEK
Jan 1, 2024
75.40 SEK
Jan 1, 2025
59.00 SEK
The Fluicell Equity Ratio history
YEAREquity RatioYoY
59.00 %-21.75%
75.40 %+1,557.11%
4.55 %-93.83%
73.81 %+4.20%
70.83 %-9.80%
78.53 %+53.11%
51.29 %-43.01%
89.99 %+8.33%
83.07 %+25.21%
66.34 %+63.08%
40.68 %-42.71%
71.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Equity Ratio of Fluicell is 59.00 % in 2025.

Equity Ratio of Fluicell changed from 75.40 % to 59.00 %, representing a -21.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Fluicell since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Fluicell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Fluicell

All Key Metrics — Fluicell